Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds

FEBS Letters

Volumn 585, Issue 8, 2011, Pages 1113-1120

  Caruana, Mario ^a   Högen, Tobias ^b   Levin, Johannes ^b   Hillmer, Andreas ^c   Giese, Armin ^c   Vassallo, Neville ^a  

^a UNIVERSITY OF MALTA   (Malta)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aggregation; Alpha synuclein; Aromatic interaction; Confocal fluorescence spectroscopy; Parkinson's disease; Polyphenol

Indexed keywords

ACETYLCYSTEINE; ALPHA SYNUCLEIN; APIGENIN; ASCORBIC ACID; BAICALEIN; BLACK TEA EXTRACT; DEFEROXAMINE; EPIGALLOCATHECHIN GALLATE; GENISTEIN; GINKGOLIDE B; MORIN; MYRICETIN; NORDIHYDROGUAIARETIC ACID; POLYPHENOL DERIVATIVE; PURPUROGALLIN TRIMETHYL ETHER; QUERCETIN; RESVERATROL; ROSMARINIC ACID; SCUTELLAREIN; TANNIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; CHELATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; FLUORESCENCE SPECTROSCOPY; IC 50; MOUSE; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STABILITY; SENSITIVITY ANALYSIS; STRUCTURE ACTIVITY RELATION;

ACETYLCYSTEINE; ALPHA-SYNUCLEIN; ANTIOXIDANTS; APIGENIN; ASCORBIC ACID; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVANONES; FLAVONOIDS; HUMANS; IRON CHELATING AGENTS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; MUTATION; PARKINSON DISEASE; PHENOLS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; RECOMBINANT PROTEINS; SPECTROMETRY, FLUORESCENCE; STRUCTURE-ACTIVITY RELATIONSHIP;

CAMELLIA SINENSIS;

EID: 79954437554     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2011.03.046     Document Type: Article

References (40)

1. A.L. Fink The aggregation and fibrillation of alpha-synuclein Acc. Chem. Res. 39 2006 628 634
2. A.J. Lees, J. Hardy, and T. Revesz Parkinson's disease Lancet 373 2009 2055 2066
3. M. Periquet, T. Fulga, L. Myllykangas, M.G. Schlossmacher, and M.B. Feany Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo J. Neurosci. 27 2007 3338 3346 (Pubitemid 46474139)
4. D. Lundvig, E. Lindersson, and P.H. Jensen Pathogenic effects of alpha-synuclein aggregation Brain Res. Mol. Brain Res. 134 2005 3 17
5. M. Farrer, J. Kachergus, L. Forno, S. Lincoln, D.S. Wang, M. Hulihan, D. Maraganore, K. Gwinn-Hardy, Z. Wszolek, D. Dickson, and J.W. Langston Comparison of kindreds with Parkinsonism and alpha-synuclein genomic multiplications Ann. Neurol. 55 2004 174 179 (Pubitemid 38166993)
6. V.N. Uversky, M. Cooper, K.S. Bower, J. Li, and A.L. Fink Accelerated alpha-synuclein fibrillation in crowded milieu FEBS Lett. 515 2002 99 103 (Pubitemid 34273905)
7. K.A. Conway, J.D. Harper, and P.T. Lansbury Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid Biochemistry 39 2000 2552 2563 (Pubitemid 30148907)
8. B.I. Giasson, J.E. Duda, I.V. Murray, Q. Chen, J.M. Souza, H.I. Hurtig, H. Ischiropoulos, J.Q. Trojanowski, and V.M. Lee Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions Science 290 2000 985 989
9. K.A. Conway, J.C. Rochet, R.M. Bieganski, and P.T. Lansbury Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct Science 294 2001 1346 1349 (Pubitemid 33063102)
10. H. Fujiwara, M. Hasegawa, N. Dohmae, A. Kawashima, E. Masliah, M.S. Goldberg, J. Shen, K. Takio, and T. Iwatsubo Alpha-synuclein is phosphorylated in synucleinopathy lesions Nat. Cell Biol. 4 2002 160 164
11. J.E. Galvin, B. Giasson, H.I. Hurtig, V.M. Lee, and J.Q. Trojanowski Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology Am. J. Pathol. 157 2000 361 368 (Pubitemid 30626903)
12. R. Sharon, I. Bar-Joseph, M.P. Frosch, D.M. Walsh, J.A. Hamilton, and D.J. Selkoe The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease Neuron 37 2003 583 595 (Pubitemid 36262981)
13. D.A. Amer, G.B. Irvine, and O.M. El-Agnaf Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders Exp. Brain Res. 173 2006 223 233 (Pubitemid 44264886)
14. N. Vassallo Polyphenols and Health: New and Recent Advances 2008 Nova Science Publishers, Inc. New York
15. M. Zhu, S. Rajamani, J. Kaylor, S. Han, F. Zhou, and A.L. Fink The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils J. Biol. Chem. 279 2004 26846 26857 (Pubitemid 38812518)
16. D.E. Ehrnhoefer, J. Bieschke, A. Boeddrich, M. Herbst, L. Masino, R. Lurz, S. Engemann, A. Pastore, and E.E. Wanker EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat. Struct. Biol. 15 2008 558 566 (Pubitemid 351799141)
17. J. Bieschke, J. Russ, R.P. Friedrich, D.E. Ehrnhoefer, H. Wobst, K. Neugebauer, and E.E. Wanker EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity Proc. Natl. Acad. Sci. USA 107 2010 7710 7715
18. J.N. Rao, V. Dua, and T.S. Ulmer Characterization of alpha-synuclein interactions with selected aggregation-inhibiting small molecules Biochemistry 47 2008 4651 4656 (Pubitemid 351555485)
19. K. Ono, and M. Yamada Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro J. Neurochem. 97 2006 105 115
20. M. Masuda, N. Suzuki, S. Taniguchi, T. Oikawa, T. Nonaka, T. Iwatsubo, S. Hisanaga, M. Goedert, and M. Hasegawa Small molecule inhibitors of alpha-synuclein filament assembly Biochemistry 45 2006 6085 6094 (Pubitemid 43727101)
21. D.P. Hong, A.L. Fink, and V.N. Uversky Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein J. Mol. Biol. 383 2008 214 223
22. X. Meng, L.A. Munishkina, A.L. Fink, and V.N. Uversky Molecular mechanisms underlying the flavonoid-induced inhibition of alpha-synuclein fibrillation Biochemistry 48 2009 8206 8224
23. A. Giese, B. Bader, J. Bieschke, G. Schaffar, S. Odoy, P.J. Kahle, C. Haass, and H. Kretzschmar Single particle detection and characterization of synuclein co-aggregation Biochem. Biophys. Res. Commun. 333 2005 1202 1210 (Pubitemid 40910130)
24. K.M. Danzer, D. Haasen, A.R. Karow, S. Moussaud, M. Habeck, A. Giese, H. Kretzschmar, B. Hengerer, and M. Kostka Different species of alpha-synuclein oligomers induce calcium influx and seeding J. Neurosci. 27 2007 9220 9232 (Pubitemid 47312071)
25. M. Kostka, T. Högen, K.M. Danzer, J. Levin, M. Habeck, A. Wirth, R. Wagner, C.G. Glabe, S. Finger, U. Heinzelmann, P. Garidel, W. Duan, C.A. Ross, H. Kretzschmar, and A. Giese Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers J. Biol. Chem. 283 2008 10992 11003
26. A.S. Hillmer, P. Putcha, J. Levin, T. Högen, B.T. Hyman, H. Kretzschmar, P.J. McLean, and A. Giese Converse modulation of toxic alpha-synuclein oligomers in living cells by N′-benzylidene-benzohydrazide derivates and ferric iron Biochem. Biophys. Res. Commun. 391 2010 461 466
27. K. Aaby, E. Hvattum, and G. Skrede Analysis of flavonoids and other phenolic compounds using high-performance liquid chromatography with coulometric array detection: relationship to antioxidant activity J. Agric. Food Chem. 52 2004 4595 4603
28. C.A. Rice-Evans, N.J. Miller, and G. Paganga Structure-antioxidant activity relationships of flavonoids and phenolic acids Free Radic. Biol. Med. 20 1996 933 956 (Pubitemid 26157509)
29. R. Borghi, R. Marchese, A. Negro, L. Marinelli, G. Forloni, D. Zaccheo, G. Abbruzzese, and M. Tabaton Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects Neurosci. Lett. 287 2000 65 67 (Pubitemid 30332379)
30. L. Baum, and A. Ng Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models J. Alzheimers Dis. 6 2004 367 377 (Pubitemid 39287248)
31. Y. Porat, A. Abramowitz, and E. Gazit Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism Chem. Biol. Drug Des. 67 2006 27 37 (Pubitemid 43881385)
32. W.M. Berhanu, and A.E. Masunov Natural polyphenols as inhibitors of amyloid aggregation. Molecular dynamics study of GNNQQNY heptapeptide decamer Biophys. Chem. 149 2010 12 21
33. W. Zhou, A. Gallagher, D.P. Hong, C. Long, A.L. Fink, and V.N. Uversky At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillation J. Mol. Biol. 388 2009 597 610
34. K.A. Youdim, M.Z. Qaiser, D.J. Begley, C.A. Rice-Evans, and N.J. Abbott Flavonoid permeability across an in situ model of the blood-brain barrier Free Radic. Biol. Med. 36 2004 592 604 (Pubitemid 38230176)
35. M. Singh, M. Arseneault, T. Sanderson, V. Murthy, and C. Ramassamy Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms J. Agric. Food Chem. 56 2008 4855 4873 (Pubitemid 352039080)
36. L.C. Tan, W.P. Koh, J.M. Yuan, R. Wang, W.L. Au, J.H. Tan, E.K. Tan, and M.C. Yu Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study Am. J. Epidemiol. 167 2008 553 560 (Pubitemid 351323310)
37. T. Hamaguchi, K. Ono, A. Murase, and M. Yamada Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway Am. J. Pathol. 175 2009 2557 2565
38. K. Rezai-Zadeh, G.W. Arendash, H. Hou, F. Fernandez, M. Jensen, M. Runfeldt, R.D. Shytle, and J. Tan Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice Brain Res. 1214 2008 177 187
39. A. Smith, B. Giunta, P.C. Bickford, M. Fountain, J. Tan, and R.D. Shytle Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease Int. J. Pharm. 389 2010 207 212
40. D.P. Karpinar, M.B. Balija, S. Kügler, F. Opazo, N. Rezaei-Ghaleh, N. Wender, H.Y. Kim, G. Taschenberger, B.H. Falkenburger, H. Heise, A. Kumar, D. Riedel, L. Fichtner, A. Voigt, G.H. Braus, K. Giller, S. Becker, A. Herzig, M. Baldus, H. Jäckle, S. Eimer, J.B. Schulz, C. Griesinger, and M. Zweckstetter Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models EMBO J. 28 2009 3256 3268